Astellas Announces Acquisition of Quethera
Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program…read more
Oliver Sexton joined Midven in April 2014 to manage the UK Innovation & Science Seed Fund’s synthetic biology investments.
Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies At Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics.
Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy.
Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.
Position Investment Director
Telephone 0121 710 1990
“Turning world-leading research into profitable companies is no simple matter, but we are now at a point where many of those technologies are suitable for broad commercial application. The UK Innovation & Science Seed Fund is providing not just capital, but the expertise and the networks to maximize the chances of success in existing markets and in the new markets that synthetic biology enables.”
8th May 2017 Nemesis Bioscience today announced the successful completion of its latest funding round,…read more